Gemcitabine in NK/T Cell Lymphoma

N/ACompletedNCT01660568

Samsung Medical Center20 enrolled

Overview

We retrospectively review patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen

Study Type

OBSERVATIONAL

Enrollment

Sex: ALLMin age: 15 Years

Medical Language ↔ Plain English

Inclusion Criteria: * NK/T cell lymphoma * relapse or refractory disease * gemcitabine containing treatment Exclusion Criteria:

Samsung Medical Center

Seoul, South Korea

Overall response rate

Time frame: 2012-May

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.